NCT05892068View on ClinicalTrials.gov

A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 9, 2023

Primary Completion Date

May 9, 2028

Study Completion Date

May 9, 2028

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Tucatinib

Standard dose of 300mg orally twice daily for 4 days prior to surgery (day -4 to 0).

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering Cancer Center (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Seagen Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT05892068 - A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain | Biotech Hunter | Biotech Hunter